Kamada (KMDA) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.14
- Estimate
- $0.13
- Surprise
- +9.8%
- Score today
- 6.5/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Kamada (KMDA) beat the $0.13 estimate with adjusted EPS of $0.14 — a clear 9.8% upside surprise.
Coverage in the report window
- Kamada Reports Record Financial Results and Increases 2026 Annual Guidance — fiscal.ai, 2026-11-09
- Kamada Q3 2026 Earnings Call Transcript — benzinga, 2026-11-09
- Kamada Q3 EPS $0.14 Beats $0.13 Estimate, Sales $52.034M Miss $52.506M Estimate — benzinga, 2026-11-09
Where TrendMatrix's rating stands now
TrendMatrix currently rates KMDA Sell at 6.5/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +9.8% surprise compares with a -2.4% four-quarter average.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Attractive valuation
What argues against it
- Consecutive earnings misses (2)
- News modifier -1: HOLD_IF_HOLDING → SELL_IF_HOLDING
- Insider activity: 0.37%=heavy
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $8.06
- Price target
- $11.47
- Stop
- $7.50
- Upside to target
- +42.3%
- Reward-to-risk
- 2.8:1
The stock trades at 20.3× trailing but 13.3× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-11-10 — shown for context, not personalized investment advice.
KMDA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $444.9M
- P/E (fwd)
- 13.3
- P/E (ttm)
- 20.3
- 52-week range
- $6.60–$9.35
- Off 52-week high
- 13.8%
- RSI (14)
- 55
- Volume vs avg
- 1.12×
- Score today
- 6.5/10